Rationale: Sufficient levels of vitamin D seem to be essential for proper immune function, and low levels might be associated to disease activity in Rheumatoid 
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| INTRODUCTION
Besides its well-known function in calcium homeostasis, vitamin D is also a potent immune-modulator, meant to affect the disease activity and course of several autoimmune diseases, including Rheumatoid Arthritis (RA).
Cells of the immunesystem contain enzymes essential for conversion of the "pre-hormone" 25OHD to the physiologically active metabolite 1,25(OH) 2 D, as well as vitamin D receptors, responsible for the altered gene transcription and thereby maturation and differentiation of the immune cells. Vitamin D orchestrates the immune system by affecting pivotal cytokines in the delicate balance which maintains immunological homoeostasis. [1] [2] [3] Briefly, sufficient levels of 1,25(OH) 2 D lead to a self-accepting Th2 and Threg response, dominated by cytokines such as Interleukin (IL)4, IL5 and IL10, 4 whereas insufficient levels lead to a self-aggressive Th1 and Th17 response, dominated by interferon gamma, IL1, IL6 and IL17. 5 In the classic calcium metabolism, most vitamin D circulates as the inactive metabolite 25OHD, which through hepatic and renal hydroxylation is converted to the physiologically active 1,25(OH) 2 D. Most 25OHD is bound to vitamin D binding protein (VDBP), which protects against degradation and renal elimination, thereby prolonging the half-life, but also sequesters 25OHD, which diminishes the bio-availability. 6 25OHD has a relatively long half-life on 5-6 weeks, whereas the half-life of 1,25(OH) 2 D is only hours. 7 The conversion of circulating 25OHD to 1,25 8 and the level of circulating 25OHD is therefore widely used as a marker of the body′s vitamin D reserves. Sufficient levels of 25OHD are above 50 nmol/L, while lower levels are leading to compensatory secondary hyperparathyroidism. Levels below 25 nmol/L are considered very low, as the secondary hyperparathyroidism is accelerated and the bone turnover increases. 8, 9 Although, in some chronic inflammatory conditions, such as sarcoidosis and RA, a local, non-renal production of 1,25(OH) 2 D might contribute significantly to the systemic concentration.
10,11
The local vitamin D metabolism in T-lymphocytes, dendritic cells, monocytes and macrophages is affected by cellactivation status: Antigen presenting cells constantly express vitamin D Receptor, whereas it is inducible in T-lymphocytes upon activation. 3, [12] [13] [14] Also enzymes responsible for conversion to active 1,25(OH) 2 D, and further inactivation (1-α-hydroxylase and 24-α-hydroxylase, respectively), are expressed by macrophages and dendritic cells when activated. 3 The local enzymatic activity is in 3 with high sensitivity and specificity, whereas RIA evaluates both metabolites as one. Both methods show reliable sensitivity in the normal range, whereas LC-MS/MS has higher sensitivity than RIA when evaluating very low levels.
Generally, the correlation between RIA and LC-MS/MS is good when evaluating 1,25(OH) 2 D. 25 Rheumatoid Arthritis is a classic systemic, autoimmune disease that leads to joint swelling, erosions and disability. Patients are often affected by comorbidities, such as osteoporosis, and systemic disease manifestations, mainly in the cardiopulmonal system. 26 The aetiology of RA is not fully known, but is meant to be multifactorial, with genetic as well as environmental factors leading to lack of immunological self-acceptance, caused by an aggressive, Th1-driven immune response against the synovialis. Main proinflammatory cytokines in RA are tumour necrotizing factor, IL6 and IL17. 27 Owing to the immunomodulatory properties of vitamin D, associations between vitamin D metabolites and RA disease course are widely studied. Vitamin D levels in RA patients are often low, but it is not known if it is the cause or the consequence of the disease. 5 In RA cell cultures, 1,25(OH) 2 D are shown to affect immune-cell maturation and differentiation, 5 and to directly affect main pro-inflammatory cytokines, such as TNF, IL1, IL6, 28 as well as IL17. 29 Human studies have mainly focused on the commonly measured 25OHD: 30 In chronic RA patients, treated with Disease-Modifying Anti-Rheumatic Drugs (DMARDs), studies found divergent associations between 25OHD levels and disease activity with a tendency towards an inverse association, confirmed in a recent meta-analysis. 30 On the contrary, the physiological active 1,25(OH) 2 D is only rarely evaluated in vivo in RA cohorts, and a recent meta-analysis found studies evaluating 1,25(OH) 2 D in RA too sparse to a separate meta-analysis. 31 Although scientific work in the field of the physiological active metabolite seems to increase, a recent study indicate that the in vitro association with a proinflammatory milieu is also found in human studies. 32 The mounting evidence that vitamin D, and especially 1,25(OH) 2 D is involved in the immune-homoeostasis, and that low levels of vitamin D seem to predispose to a pro-inflammatory state, makes it relevant to evaluate associations between circulating levels of all vitamin D metabolites and their association to disease activity in RA patients with systemic inflammation.
The aim of this study was, in inflammatory active and treatment naïve early RA patients, to quantify serum levels of 25OHD 2 , 25OHD 3 and 1,25(OH) 2 D at the time of diagnosis and to test the prespecified hypothesis that associations exist to RA disease-activity parameters.
| MATERIALS AND METHODS

| Patients
One hundred and sixty patients were recruited from five Danish University Clinics from October 1999 to October HERLY ET AL.
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2002. They participated in the CIMESTRA study, eligibility criteria and selection of participants are described elsewhere, 33 baseline characteristics are listed in Table 1 . Participant′s received oral and written information prior to inclusion. Written consent was given before enrolment.
The study was in compliance with the Helsinki declaration and approved by the national health authorities and local ethics committee (M-1959-98) and is registered at www.c linicaltrials.gov (Ref. number: NCT00209859).
| Measuring vitamin D metabolites
Serum 25OHD 2 and 25OHD 3 were analysed by isotopedilution liquid chromatography-mass spectrometry (LC-MS/ MS). 34 
| Routine laboratory assessments
IgM-RF was detected by enzyme-linked immunosorbent assay. ACPA IgG antibodies were determined by a secondgeneration enzyme-linked immunosorbent assay (Immunoscan RA kit; Euro-diagnostica AB, Malmo, Sweden) with the recommended 25 U/mL cut-off point. Serum CRP was measured using standard technique.
| Reporting
Reporting of the results conform to the "Strengthening the Reporting of Observational Studies in Epidemiology" (STROBE) statement for cross-sectional studies.
| Statistics
Univariate associations between the independent variable, evaluated as continuous vitamin D metabolite levels, and the dependent variables; NTJ, NSJ, DAS28-CRP, CRP, HAQ, VAS patient-pain , VAS global-patient and VAS global-doctor , were evaluated using Spearman's test. Wilcoxon rank-sum test evaluated associations between vitamin D metabolite levels and the sub-groups IgM-RF positive vs negative patients, ACPA-status positive vs negative patients, erosive status evaluated as non-erosive disease (TSS = 0) or erosive disease (TSS > 0), and season of diagnosis, dichotomized as summer or winter (winter defined as diagnosis established from November to April). Significance was defined as the 5% level. The "R" software package was used, and analyses were performed by an independent statistician. 
| RESULTS
Sixty-nine patients (42%) had low D total , (below 50 nmol/ L). Fifteen patients (10%) had very low levels below 25 nmol/L. Sixteen patients (10%) had low 1,25(OH) 2 D levels, (below 60 pmol/L). The majority of these (75%) had concomitantly low D total . Statistically significant inverse associations were found between 1,25(OH) 2 D (median 95 pmol/L, range 33-268), and RA disease variables as DAS28-CRP (rho = −0.23, P = 0.004), HAQ (rho = −0.22, P = 0.005), CRP (rho = −0.25, P = 0.001), and VAS patient-pain (rho = −0.21, P = 0.008). There were no significant associations to NSJ (rho = −0.09, P = 0.24), NTJ (rho = −0.09, P = 0.26), VAS global-patient (rho = −0.14, P = 0.08) or VAS global-doctor (rho = −0.14, P = 0.09). Significant positive association was found between 1,25(OH) 2 D and ACPA-status (P = 0.04); but not to IgM-RF status (P = 0.35), nor to erosive or non-erosive status at baseline (P = 0.29; Figure 1 ).
Median 25OHD 2 was 0 nmol/L (range 0-37). This was significantly inversely associated with NTJ (rho = −0.17, P = 0.03) and not to other variables ( Figure 1 and Table 2 ).
Median 25OHD 3 was 52 nmol/L (range 0-145), and this was not associated to any variables, Table 2 .
Seasonal variation was found for 25OHD 3 , with significantly lower levels in patients diagnosed during the winter (P = 0.003). No significant seasonal variation in levels of 25OHD 2 (P = 0.46) and 1,25(OH) 2 D (P = 0.15) was found (for all results, Table 2 ).
Concerning missing data, three patients had missing values of vitamin D metabolite levels at baseline and three patients had missing values of CRP and therefore of DAS28. There are no indications that these data were not missing at random, and therefore, these patients were not excluded during the analyses.
| DISCUSSION
This study is one of few human studies investigating all vitamin D metabolites. Main finding is, in 160 early diagnosed, treatment-naive RA patients that low serum levels of 1,25(OH) 2 D are associated to several parameters for RA disease activity, including CRP, HAQ, VAS patient-pain and DAS28-CRP. Despite 90% of the cohort had 1,25(OH) 2 D in the normal range, there were several strong associations to markers for disease activity when evaluating the metabolite as a continuous variable. This was chosen prior to analyses, to investigate if levels lower in the normal range were associated with markers of disease activity. We find this approach to be relevant because of the gap in knowledge concerning cut-offs in vitamin D metabolites and proper immune-function. Even though 1,25(OH) 2 D is closely regulated under normal physiological conditions, 3 our results indicate that the regulation might be disturbed during systemic inflammation.
Activation status and cytokine production of T-lymphocytes and antigen presenting cells affect the local vitamin D metabolism, leading to increased local 1,25(OH) 2 D synthesis. 3, [12] [13] [14] 36 It is somewhat contra-intuitive to our results, where lower levels of 1,25(OH) 2 D are associated with elevated markers of disease activity, including markers of systemic inflammation, such as CRP and DAS28CRP, and denotes that much is still unknown concerning vitamin D and inflammation in RA as well as in non-RA subjects.
Our study adds to the literature that 25OHD, a commonly used marker for the body's vitamin D reserve, is not associated with RA-disease activity or diagnostic criteria in early, treatment-naive RA patients. Further, the tradition of only measuring 25OHD when assessing vitamin D status in RA patients is challenged by our results.
As expected, 25OHD levels showed seasonal variation, owing to increased cutaneous production during sun exposure in the summer. 37 This is a factor that must be taken into consideration, whenever studying associations with 25OHD. In small studies, this weakens the power, whereas our finding of no seasonal variation in 1,25(OH) 2 Our finding of an inverse association between 1,25 (OH) 2 D and CRP has also been observed in healthy subjects. 39 A possible explanation is interaction between vitamin D, calcium homoeostasis and IL-6, affecting the production of acute-phase reactants. 40 The association of 1,25(OH) 2 D with CRP and ACPA and of 25OH 2 D with NTJ add credit to the notion that the level of vitamin D metabolites may influence on diagnostic specificity and sensitivity associated with the ACR/ EULAR2010 classification criteria for RA. 26 45 This is not confirmed in human studies. In our human RA study, the serum level of vitamin D metabolites was not associated with the TSS, thereby supporting that no association exists between vitamin D metabolites and RA erosions. This study has some limitations. The cross-sectional design does not investigate causality, and it can be argued that the associations of low vitamin D metabolite levels to RA disease activity are the consequence rather than the cause of the disease. Moreover, vitamin D status is the result of a delicate interplay with both immune-cells and calcium-homoeostasis, and a limitation in our study is the lack of measuring calcium, phosphate, parathyroid hormone and albumin.
Furthermore, a common challenge in vitamin D studies is the vitamin D measurement method, as great variability between methods exists, thereby affecting the between-studies comparability. 19, 20 In this study, 25OHD 2 and 25OHD 3 were measured using LS-MS/MS, which detects D 2 and D 3 separately, whereas 1,25(OH) 2 D was measured with RIA, which detects both D 2 and D 3 -derived 1,25 (OH) 2 D. 35 We find the variation coefficients provided by the suppliers acceptably low across the low and normal range. 34, 35 Possible confounders are adiposity, physical capacity, age and renal disease, which all are associated with both vitamin D deficiency and RA disease activity. The lipophilic vitamin D clusters in adipose tissue and leads to lower levels of circulating vitamin D, and adipose tissue is known to contribute to inflammation in RA. 46 Physical inactivity is common in RA and is associated with inflammatory activity, pain and fatigue, 47 whereas some studies also associate physical inactivity with lower vitamin D levels, including 1,25(OH) 2 D. 48 Low vitamin D levels are common in the elderly 8 and in patients with renal insufficiency. The exclusion of patients over 75 years of age and patients with renal insufficiency could lead to underestimation of the prevalence of vitamin D deficiency in our cohort, compared to the general population, thereby weakening the external validity. The strengths of our study are the well characterized, early and treatment-naïve RA patients and the measurement of both 25OHD and 1,25(OH) 2 D serum levels.
The novelty of this study is the evaluation of all vitamin D metabolites, compared to the vast amount of reports in 25OHD only. We find it relevant to investigate this gap in knowledge, as the 1,25(OH) 2 D is the physiologically active metabolite, which is responsible for the immunological actions of vitamin D, as well as in the calcium homeostasis. That said, knowledge concerning calcium homoeostasis suggests that sufficient levels of circulating D total are necessary for local conversion to 1,25(OH) 2 In summary, our study revealed biological plausible associations between circulating 1,25(OH) 2 D and several parameters relevant for diagnosis and assessment of disease activity in a cohort of inflammatory active and treatmentnaïve early RA patients. These results are likely applicable in early RA patients of Scandinavian ancestry. In future studies, we recommend measurement of all vitamin D metabolites as well as calcium, phosphate, parathyroid hormone and albumin to evaluate the interplay between vitamin D metabolites and calcium metabolism in RA.
